In vitro and In vivo Assessment of Pi3KÃÂ³ Inhibitors for Anti-Inflammatory Indications: Challenges of Selectivity over Pi3KÃÂ±David Lamb*, Graham Lunn, Mark O’Reilly, Cheryl Butler and Iain Kilty
Pfizer Global Research and Development, Sandwich Laboratories, United Kingdom
- *Corresponding Author:
- David Lamb
Pfizer Global Research and Development
Sandwich Laboratories, Ramsgate Road
Sandwich, Kent, CT13 9NJ, United Kingdom
Fax: 49-7351- 5498674
E-mail: [email protected]
Received date: March 16, 2013; Accepted date: September 24, 2013; Published date: September 26, 2013
Citation: Lamb D, Lunn G, O’Reilly M, Butler C, Kilty I (2013) In vitro and In vivo Assessment of Pi3K? Inhibitors for Anti-Inflammatory Indications: Challenges of Selectivity over Pi3Ka. J Pulm Respir Med 3:157. doi: 10.4172/2161-105X.1000157
Copyright: © 2013 Lamb D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Class 1 PI3Ks are a growing area of interest as pharmacological targets across a number of disease mechanisms. We have assessed the feasibility of developing selective PI3Kgamma inhibitors based upon the ATP-binding hinge site. Following full file screening, 8800 analogues representing 25 chemotypes were further analysed across a panel of PI3K enzymes and cellular assays. Despite this we did not identify a series of compounds which possessed all required criteria of potency, selectivity, metabolic stability and solubility. We profiled the best 3 compounds in vivo to assess their anti-inflammatory efficacy versus PI3Kalpha driven perturbations in glucose/insulin homeostasis. Each compound dose-dependently inhibited LPS elicited pulmonary neutrophilia in rat with a marginal therapeutic index over a subsequent increase in glucose and insulin elevation. In our opinion these studies provide no evidence of a divergence from enzyme selectivity to an in vivo therapeutic index over insulin and glucose perturbations and therefore there is no evidence to suggest ATP competitive hinge binding site PI3Kgamma inhibitors will afford sufficient in vivo TI worthy of clinical progression for inflammatory indications.